MDVN

Medivation Inc

A San Francisco biopharmaceutical company that develops medicines for serious illnesses, best known for Xtandi (enzalutamide), an oral prostate cancer drug it co-developed and marketed with Japan's Astellas. Oncologist David Hung and investor Steve Gorlin founded the firm in 2003, after Hung—moved by a young breast cancer patient's death during his fellowship—resolved to do something about such diseases. Its name blends "medical" and "innovation." In 2016 Pfizer bought the company and absorbed it.

Recent Activity

Show $

2016Q4

1 sell

Torray Investment PartnersEXIT

-28.2K shares

Torray Investment PartnersEXIT

-28.2K shares

2016Q3

2 sells

Maverick CapitalEXIT

-52.6K shares

Maverick CapitalEXIT

-52.6K shares

Torray Investment PartnersTRIM

-559.6K shares(-95.2%)

Torray Investment PartnersTRIM

-559.6K shares(-95.2%)

2016Q2

1 buy2 sells

Maverick CapitalNEW

+52.6K shares

Maverick CapitalNEW

+52.6K shares

Torray Investment PartnersTRIM

-418.0K shares(-41.6%)

Torray Investment PartnersTRIM

-418.0K shares(-41.6%)

Viking Global InvestorsEXIT

-707.3K shares

Viking Global InvestorsEXIT

-707.3K shares

2016Q1

2 buys

Torray Investment PartnersADD

+212.8K shares(+26.8%)

Torray Investment PartnersADD

+212.8K shares(+26.8%)

Viking Global InvestorsNEW

+707.3K shares

Viking Global InvestorsNEW

+707.3K shares

Loading more activity...